+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Resorbable Vascular Scaffold Market - Global Forecast 2026-2032- Product Image
Resorbable Vascular Scaffold Market - Global Forecast 2026-2032- Product Image
Sale

Resorbable Vascular Scaffold Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012364
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Resorbable Vascular Scaffold Market is projected to reach USD 500.68 Million in 2026. It is expected to continue growing at a CAGR of 7.68%, reaching USD 779.98 Million by 2032.

Resorbable vascular scaffolds (RVS) represent a next-generation coronary intervention platform designed to provide temporary vessel support and drug delivery, then gradually resorb to help restore vasomotion, reduce permanent metallic caging, and preserve future treatment options. The resorbable vascular scaffold market remains shaped by lessons from first-generation bioresorbable vascular scaffold programs, including the FDA-approved Absorb GT1 BVS, which was later withdrawn from commercial sale after clinical and adoption challenges, including concerns identified in comparative clinical follow-up.

Current opportunity is concentrated in improved scaffold architecture, thinner struts, magnesium and polymer platforms, optimized implantation protocols, and better patient and lesion selection. For manufacturers, the competitive path is no longer based on novelty alone; it depends on demonstrating clinical noninferiority or superiority versus contemporary drug-eluting stents, durable safety, predictable resorption, and procedural efficiency in real-world catheterization labs.

Transformative Shifts Reshaping RVS Innovation

The resorbable vascular scaffold landscape is shifting from first-generation enthusiasm to evidence-led product discipline. Earlier polymeric scaffolds showed the clinical importance of strut thickness, radial strength, expansion limits, and implantation technique. As a result, next-generation development is prioritizing thinner profiles, improved deliverability, shorter and more predictable resorption timelines, and more consistent vessel healing.

Regulatory expectations have also transformed. The U.S. FDA, European regulators under the Medical Device Regulation, and major Asian agencies increasingly require robust randomized data, long-term follow-up, and post-market surveillance. This favors organizations with strong clinical operations, material science expertise, imaging-guided procedure support, and physician education models that reduce scaffold thrombosis risk through correct sizing, lesion preparation, and high-pressure post-dilatation.

Cumulative Impact of Artificial Intelligence on RVS

Artificial intelligence is cumulatively improving the RVS value chain by strengthening design, trial execution, and clinical decision support. In R&D, AI-enabled simulation can evaluate scaffold geometry, radial force, degradation behavior, and vessel interaction before costly prototyping. Machine learning applied to intravascular imaging may also support more precise vessel sizing, calcium assessment, plaque characterization, and lesion selection.

In clinical development, AI can improve site selection, patient stratification, adverse-event signal detection, and real-world evidence generation. Its most immediate commercial impact is likely to be procedural optimization: integrating angiography, OCT, IVUS, and electronic health record data to identify patients most likely to benefit from temporary scaffolding while reducing inappropriate use in complex lesions where metallic drug-eluting stents remain better validated.

Key Regional Insights for RVS Adoption

Asia-Pacific is becoming an important RVS development and adoption arena because China, Japan, India, South Korea, and Australia combine high cardiovascular disease burden with expanding interventional cardiology capacity. Japan and South Korea emphasize rigorous clinical evidence, precision manufacturing, and quality systems, while China and India offer large procedural volumes, improving hospital infrastructure, and growing domestic medtech innovation. Australia contributes a registry-oriented and evidence-based adoption environment that supports careful evaluation of new coronary scaffold technologies.

North America remains evidence-driven, with the United States and Canada requiring strong safety data after the first-generation bioresorbable vascular scaffold experience. Europe continues to influence clinical standards through high-volume research centers and interventional cardiology networks, although Medical Device Regulation requirements have raised evidence, documentation, and compliance thresholds. Latin America, led by Brazil and Mexico, presents selective opportunities where adoption will depend on pricing discipline, reimbursement clarity, and training access. The Middle East, particularly advanced tertiary systems in Gulf countries, shows potential for premium cardiovascular technologies where specialist infrastructure is available, while Africa remains a longer-term opportunity constrained by uneven cath lab access, affordability, and advanced imaging availability.

Key Group Insights Across Strategic Market Blocs

ASEAN markets are attractive for future RVS expansion because urban cardiac centers in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are upgrading cath lab capabilities, but reimbursement and training variability require staged commercialization and physician education. The GCC is characterized by high cardiovascular risk factors, advanced tertiary hospitals, and strong demand for premium cardiovascular technologies, particularly where government-funded care and specialist referral systems support adoption of advanced interventional cardiology devices.

The European Union remains central for clinical evidence generation, harmonized regulatory scrutiny, and post-market vigilance, but Medical Device Regulation compliance increases documentation, clinical evaluation, and surveillance obligations. BRICS countries offer procedural scale, local manufacturing potential, and diverse access models, with China and India especially relevant for domestic device development and clinical volume. G7 markets set expectations for long-term safety, reimbursement evidence, registry transparency, and physician consensus. NATO membership is not a market driver by itself, but many NATO countries overlap with advanced procurement, regulatory, and hospital systems relevant to cardiovascular devices.

Key Country Insights in Resorbable Scaffold Markets

The United States is the most influential RVS market for regulatory credibility, but adoption depends on clear long-term safety and comparative outcomes versus leading drug-eluting stents, supported by rigorous clinical follow-up and real-world evidence. Canada follows evidence-based procurement and reimbursement scrutiny, while Mexico and Brazil offer regional volume potential if pricing, imaging access, and operator training barriers are addressed. The United Kingdom, Germany, France, Italy, and Spain remain important European clinical hubs, with Germany particularly relevant for interventional cardiology innovation, hospital-based evaluation, and early specialist engagement.

Russia presents a more complex access environment shaped by sanctions, localization requirements, supply chain restrictions, and procurement constraints. China and India offer large patient populations, expanding interventional cardiology capacity, and active domestic device ecosystems, making them central to future RVS development and adoption strategies. Japan and South Korea demand high-quality evidence, precision manufacturing, and strong regulatory documentation, while Japan’s aging population and South Korea’s advanced hospital systems support focused evaluation of coronary innovation. Australia is a sophisticated but smaller market where reimbursement, specialist endorsement, clinical registries, and outcomes transparency strongly influence uptake.

Actionable Recommendations for RVS Industry Leaders

Industry leaders should prioritize clinically meaningful differentiation rather than broad claims of bioresorption. Development programs need predefined imaging endpoints, adequately powered randomized trials, and long-term follow-up focused on scaffold thrombosis, target lesion failure, late lumen loss, vessel healing, and restoration of vasomotion. Evidence should be benchmarked against current-generation drug-eluting stents, not against older platforms.

Commercial teams should build adoption around training-certified implantation protocols, including lesion preparation, accurate sizing, and post-dilatation. Integration with OCT and IVUS workflows can improve procedural consistency and support appropriate patient selection. Organizations should also design market access strategies early, combining health economics, registry data, and real-world evidence to demonstrate where temporary scaffolding creates value for patients, clinicians, and payers.

Research Methodology for RVS Market Analysis

This executive summary is based on a structured secondary research approach using publicly available regulatory records, peer-reviewed clinical literature, clinical trial publications, medical society discussions, product documentation, and market intelligence on interventional cardiology technologies. Emphasis is placed on verified developments such as first-generation scaffold clinical outcomes, regulatory approval pathways, commercial withdrawals, evolving device evaluation standards, and advances in coronary imaging-guided intervention.

The methodology prioritizes triangulation across clinical trials, registries, product documentation, regulatory communications, and regional healthcare infrastructure indicators. Insights are interpreted through the lens of device safety, procedural adoption, reimbursement feasibility, clinical workflow integration, and competitive positioning versus contemporary drug-eluting stents. No unverified market-size figures are used; conclusions focus on evidence-backed directional trends and strategic implications.

Conclusion: Evidence Will Define the RVS Future

The resorbable vascular scaffold market is entering a more mature phase defined by scientific rigor, selective adoption, and next-generation engineering. The category’s long-term potential remains compelling because temporary vascular support addresses an unmet clinical aspiration: treating coronary lesions without leaving a permanent implant behind.

However, the path to sustainable growth requires proof. Manufacturers must demonstrate safer scaffold design, predictable degradation, procedural reproducibility, and patient-specific value. Markets with strong clinical governance, intravascular imaging capability, trained operators, and reimbursement sophistication will likely lead early adoption, while broader global expansion will depend on cost-effectiveness, supply reliability, and training. The winners will be organizations that translate bioresorption from an appealing concept into consistently validated cardiovascular outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Resorbable Vascular Scaffold Market, by Material Type
7.1. Introduction
7.2. Polymer-based
7.2.1. Poly-L-lactic Acid (PLLA)
7.2.2. Poly-glycolic Acid (PGA)
7.2.3. Polycaprolactone (PCL)
7.2.4. Poly-dioxanone (PDO)
7.3. Metal-based
7.3.1. Magnesium Alloys
7.3.2. Iron-based Alloys
7.3.3. Zinc-based Alloys
8. Resorbable Vascular Scaffold Market, by Indication Type
8.1. Introduction
8.2. Coronary Artery Disease
8.3. Peripheral Arterial Disease
8.3.1. Femoral Artery Disease
8.3.2. Popliteal Artery Disease
8.3.3. Tibial Artery Disease
9. Resorbable Vascular Scaffold Market, by Drug Elution Type
9.1. Introduction
9.2. Drug Eluting Scaffolds
9.2.1. Sirolimus Eluting
9.2.2. Everolimus Eluting
9.2.3. Paclitaxel Eluting
9.2.4. Biolimus Eluting
9.3. Non Drug Eluting Scaffolds
10. Resorbable Vascular Scaffold Market, by Scaffold Length
10.1. Introduction
10.2. 18 To 28 Millimeter
10.3. Greater Than 28 Millimeter
10.4. Less Than 18 Millimeter
11. Resorbable Vascular Scaffold Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cardiac Centers
11.4. Hospitals
12. Resorbable Vascular Scaffold Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Resorbable Vascular Scaffold Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Resorbable Vascular Scaffold Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Balton Sp. z o.o.
16.3. Biotronik SE & Co. KG
16.4. Boston Scientific Corporation
16.5. Cook Medical LLC
16.6. Elixir Medical Corporation
16.7. Kyoto Medical Planning Co., Ltd.
16.8. Lepu Medical Technology (Beijing) Co., Ltd.
16.9. Lifetech Scientific Corporation
16.10. Meril Life Sciences Pvt. Ltd.
16.11. MicroPort Scientific Corporation
16.12. OrbusNeich Medical Company Limited
16.13. REVA Medical LLC
16.14. Sahajanand Medical Technologies Pvt. Ltd.
16.15. Terumo Corporation
16.16. Translumina Therapeutics LLP
16.17. Zorion Medical Inc.
List of Figures
FIGURE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL POLYMER-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL POLYMER-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL POLYMER-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL POLY-L-LACTIC ACID (PLLA) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL POLY-L-LACTIC ACID (PLLA) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL POLY-L-LACTIC ACID (PLLA) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL POLY-GLYCOLIC ACID (PGA) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL POLY-GLYCOLIC ACID (PGA) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL POLY-GLYCOLIC ACID (PGA) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL POLYCAPROLACTONE (PCL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL POLYCAPROLACTONE (PCL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL POLYCAPROLACTONE (PCL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL POLY-DIOXANONE (PDO) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL POLY-DIOXANONE (PDO) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL POLY-DIOXANONE (PDO) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL METAL-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL METAL-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL METAL-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MAGNESIUM ALLOYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MAGNESIUM ALLOYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MAGNESIUM ALLOYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL IRON-BASED ALLOYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL IRON-BASED ALLOYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL IRON-BASED ALLOYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ZINC-BASED ALLOYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ZINC-BASED ALLOYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ZINC-BASED ALLOYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PERIPHERAL ARTERIAL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PERIPHERAL ARTERIAL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PERIPHERAL ARTERIAL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL FEMORAL ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL FEMORAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FEMORAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL POPLITEAL ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL POPLITEAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL POPLITEAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TIBIAL ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TIBIAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TIBIAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DRUG ELUTING SCAFFOLDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DRUG ELUTING SCAFFOLDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DRUG ELUTING SCAFFOLDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SIROLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL EVEROLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PACLITAXEL ELUTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BIOLIMUS ELUTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL NON DRUG ELUTING SCAFFOLDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL NON DRUG ELUTING SCAFFOLDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NON DRUG ELUTING SCAFFOLDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL 18 TO 28 MILLIMETER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL 18 TO 28 MILLIMETER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL 18 TO 28 MILLIMETER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GREATER THAN 28 MILLIMETER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL GREATER THAN 28 MILLIMETER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL GREATER THAN 28 MILLIMETER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL LESS THAN 18 MILLIMETER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL LESS THAN 18 MILLIMETER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL LESS THAN 18 MILLIMETER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CARDIAC CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CARDIAC CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CARDIAC CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 119. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 120. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 121. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 123. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 124. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 125. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 126. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 139. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 140. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 141. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 144. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 145. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 146. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 150. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 151. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 152. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 153. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 154. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 155. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 156. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 157. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 160. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 161. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 162. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 163. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 164. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 165. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 166. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 167. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 180. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 181. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 182. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 183. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 184. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 185. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 186. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 187. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 190. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 191. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 192. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 193. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 194. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 195. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 196. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 197. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 200. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 201. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 202. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 203. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 204. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 205. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 206. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 207. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 221. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 222. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 223. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 224. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 225. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 226. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 227. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 228. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 231. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 232. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 233. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 234. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 235. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 236. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 237. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 238. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 241. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 244. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 261. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 262. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 263. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 265. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 267. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 268. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 271. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 272. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 273. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 274. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 275. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 276. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 277. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 278. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 291. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 292. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 293. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 294. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 295. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 296. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 297. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 298. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 301. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 302. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 303. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 304. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 305. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 306. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 307. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 308. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 311. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 312. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 313. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 314. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 315. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 316. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 317. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 318. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL TYPE, 2017-2032 (USD MILLION)
TABLE 321. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER-BASED, 2017-2032 (USD MILLION)
TABLE 322. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY METAL-BASED, 2017-2032 (USD MILLION)
TABLE 323. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION TYPE, 2017-2032 (USD MILLION)
TABLE 324. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2017-2032 (USD MILLION)
TABLE 325. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTION TYPE, 2017-2032 (USD MILLION)
TABLE 326. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING SCAFFOLDS, 2017-2032 (USD MILLION)
TABLE 327. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2017-2032 (USD MILLION)
TABLE 328. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. JAPAN RESORBABLE VASCULAR SCAFFO

Companies Mentioned

  • Abbott Laboratories
  • Balton Sp. z o.o.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Kyoto Medical Planning Co., Ltd.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Lifetech Scientific Corporation
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • REVA Medical LLC
  • Sahajanand Medical Technologies Pvt. Ltd.
  • Terumo Corporation
  • Translumina Therapeutics LLP
  • Zorion Medical Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 500.68 Million
Forecasted Market Value ( USD ) by 2032 $ 779.98 Million
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Resorbable Vascular Scaffolds Market Report 2026 - Product Image

Resorbable Vascular Scaffolds Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bioresorbable Vascular Scaffolds - Global Strategic Business Report - Product Image

Bioresorbable Vascular Scaffolds - Global Strategic Business Report

  • Report
  • 265 Pages
  • Global
From
Peripheral Stent Market Outlook 2026-2034: Market Share, and Growth Analysis by Product (Bare-Metal Stents (BMS), Covered Stents, Drug-Eluting Stents (DES), Bio-resorbable Vascular Scaffolds (BVS)), Artery Type, Material, Deployment Mechanism - Product Image

Peripheral Stent Market Outlook 2026-2034: Market Share, and Growth Analysis by Product (Bare-Metal Stents (BMS), Covered Stents, Drug-Eluting Stents (DES), Bio-resorbable Vascular Scaffolds (BVS)), Artery Type, Material, Deployment Mechanism

  • Report
  • 160 Pages
  • Global
From
Coronary and Endovascular Stents, An Issue of Interventional Cardiology Clinics. The Clinics: Internal Medicine Volume 15-2 - Product Image

Coronary and Endovascular Stents, An Issue of Interventional Cardiology Clinics. The Clinics: Internal Medicine Volume 15-2

  • Book
Mg Alloy Vascular Scaffold Market - Global Forecast 2026-2032 - Product Image

Mg Alloy Vascular Scaffold Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From

About the Resorbable Vascular Scaffold Market

The Resorbable Vascular Scaffold (RVS) market is a segment of the Cardiovascular Devices industry. RVS are medical devices used to treat coronary artery disease, a condition caused by the narrowing of the arteries that supply blood to the heart. RVS are designed to be implanted in the artery and gradually dissolve over time, allowing the artery to return to its natural state. This technology has been shown to reduce the risk of restenosis, a condition in which the artery becomes narrowed again after treatment. RVS are becoming increasingly popular due to their ability to reduce the risk of restenosis and the fact that they do not require a second procedure to remove the device. Additionally, RVS are less invasive than traditional stents, which require a larger incision and a longer recovery time. Some companies in the RVS market include Abbott, Biotronik, Boston Scientific, Medtronic, and Terumo. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.